InvestorBrandNetwork (IBN) logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

InvestorNewsBreaks – American Fusion Inc. (AMFN) Positions Texatron(TM) Development Around Race to Power AI

October 29, 2026 — American Fusion (OTC: AMFN) is advancing testing of its Texatron(TM) Fusion Engine(TM) as it explores opportunities to supply electricity to AI data centers and other power-intensive customers. In a recent AGORACOM interview, Executive Chairman Brent Nelson discussed the company’s 500-kW and 5-MW pre-production systems, plans for larger 10-MW and 20-MW configurations, and a development roadmap covering 12 authorized model classes ranging from approximately 500 kW to 1 GW.


InvestorNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Spotlights Drinkfinger Expansion, AI Strategy in Stock2Me Podcast

October 29, 2026 — Versus Systems (NASDAQ: VS) is expanding its audience-engagement offerings through Drinkfinger, a QR-enabled beverage carrier that connects live-event attendees with mobile games, rewards and branded content. In a recent IBN Stock2Me Podcast appearance, CEO Luis Goldner and other members of the leadership team discussed plans to target Latin American markets, including Brazil and Mexico, where sporting events, concerts and festivals offer potential opportunities for interactive promotions.


MissionIRNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Highlights Potential of GelrinC Cartilage Repair Technology

October 29, 2026 — Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed the company’s efforts to advance its regenerative cartilage repair technology, GelrinC, as orthopedic medicine increasingly emphasizes durable, long-term treatment outcomes. The company’s lead product is a cell-free, off-the-shelf degradable hydrogel implant designed to support the regeneration of knee cartilage, gradually resorbing over approximately six to nine months as new tissue fills the treated area.


BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Highlights Potential of GelrinC Cartilage Repair Technology

October 29, 2026 — Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed the company’s efforts to advance its regenerative cartilage repair technology, GelrinC, as orthopedic medicine increasingly emphasizes durable, long-term treatment outcomes. The company’s lead product is a cell-free, off-the-shelf degradable hydrogel implant designed to support the regeneration of knee cartilage, gradually resorbing over approximately six to nine months as new tissue fills the treated area.


AI Investment Drives Job Cuts Across Major Global Companies

October 29, 2026 — The race to expand AI is forcing major companies to reconsider how they spend their money, with workforce reductions emerging as one consequence. Businesses are directing more resources toward data centers, automation, and specialist talent, sometimes reducing existing positions to finance these investments.


Sales of Used EVs Soar in the US

October 29, 2026 — Used electric vehicle sales set records in September as new EV purchases fell sharply, a split that reframes the dominant narrative about American consumer appetite for electric cars. The divergence points to price as the main variable rather than any fundamental resistance to the technology.


Why Canada isn’t Going to Abandon Coal

October 29, 2026 — Canada is phasing out coal-fired electricity, but metallurgical coal presents a different economic and industrial challenge. Thermal coal is burned to generate power while metallurgical coal is used to produce coke, a key ingredient in the manufacture of steel.


Crypto Firm Shareholder Files Lawsuit Against Trump, WLF

October 29, 2026 — A shareholder in a cryptocurrency company has filed a lawsuit involving Donald Trump and WLF (World Liberty Financial), bringing fresh attention to the legal risks surrounding businesses connected to digital assets and political figures. The case raises questions about corporate decisions, shareholder rights, and the responsibilities of people linked to companies operating in the fast-changing crypto industry.


Bitcoin ETFs Bleed $773 Million in Two Days

October 29, 2026 — Bitcoin faced renewed selling pressure late last week as spot exchange-traded funds recorded heavy withdrawals. Data showed that Bitcoin spot ETFs registered combined outflows of about $773 million between October 22 and 23.


IEA Chief Commends China’s Role in Accelerating the Energy Transition Globally

October 29, 2026 — Fatih Birol, executive director of the International Energy Agency, has credited China with driving meaningful progress in the global energy transition, saying the country’s clean energy achievements have set a pace that other economies have struggled to match. Birol made the remarks at the Berlin Global Dialogue, where the energy market upheaval following the outbreak of Middle East hostilities dominated the agenda.


AINewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTFD) Featured in AINewsWire Editorial on AI-Driven Semiconductor Equipment Demand

October 29, 2026 — Nightfood Holdings (OTCQB: NGTFD), operating as TechForce Robotics, announced its placement in an AINewsWire editorial titled “Semiconductor Equipment Market Outlook: How AI Demand Is Driving Test, Packaging and Inspection Growth. ” The editorial examines how growing demand for artificial intelligence (“AI”) infrastructure is driving investment in semiconductor manufacturing, testing, packaging and inspection equipment.


BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Strategic Review to Maximize Value of Oncology Portfolio

October 29, 2026 — TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its oncology portfolio, including lead product candidate TTX-MC138. The review will consider potential licensing or sales of individual assets, development and commercialization partnerships, portfolio transactions, business combinations and other strategic alternatives.